MetaCap

Cardiol Therapeutics (CRDL) vs Voyager Therapeutics (VYGR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiol Therapeutics (CRDL) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 11.3% versus a loss of 63.4%. Over five years, VYGR leads with a -50.0% price change compared with -60.1% for CRDL. Cardiol Therapeutics is the larger company by market cap ($110.1 million vs $95.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDL-11.35%VYGR-63.40%
+145%+36%-74%
Nov 21, 20251 yearNov 20, 2026
CRDL-57.92%VYGR-53.50%
+319%+112%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDL versus VYGR key metrics
MetricCRDLVYGR
Share price$0.8626$1.53
Market cap$110.14M$95.21M
1-day change-2.28%-4.97%
YTD return-9.58%-61.07%
1-year return-11.35%-63.40%
5-year return-60.06%-50.00%
EPS (TTM)$-0.24$-1.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$40.37M
Revenue growth (YoY)—-49.53%
Net income (latest FY)—$-119.72M
Operating margin—-326.56%
Net margin—-296.53%
52-week high$2.34$5.48
52-week low$0.8417$1.48
Distance from 52-week high-63.14%-72.08%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+874.96%+829.41%
Average volume1.20M770.24K
Shares outstanding127.69M62.23M
Employees18141
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDL has outperformed VYGR by 52.1 percentage points over the past year.

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About Voyager Therapeutics

VYGR stock →

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

CRDL vs VYGR FAQ

Which is bigger, Cardiol Therapeutics or Voyager Therapeutics?

Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $110.14M compared with $95.21M for Voyager Therapeutics (VYGR).

Which stock has performed better over the past year, CRDL or VYGR?

CRDL returned -11.35% over the past 12 months, compared with -63.40% for VYGR (price return, excluding dividends). Past performance does not predict future results.

Are Cardiol Therapeutics and Voyager Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons